• Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral Foundayo, while also committing an additional US$4.50 billion to expand Indiana manufacturing for its incretin and genetic medicine portfolio.
• The combination of durable weight-loss data and large-scale production build-out underscores how central obesity and metabolic drugs have become to Lilly’s broader pharmaceutical strategy.
• We’ll now examine how the long-term weight maintenance data for Foundayo and Zepbound may reshape Eli Lilly’s existing investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you need to believe obesity and metabolic medicines remain the core growth engine, and that Lilly can keep converting scientific wins into durable, high-margin franchises. The new long-term maintenance data for Zepbound and Foundayo support the near term catalyst of expanding GLP‑1 use beyond initial weight loss, while the biggest current risk remains heavy reliance on a small group of incretin drugs in the face of intensifying competition and pricing pressure.

Among recent announcements, Lilly’s additional US$4.50 billion investment in Indiana manufacturing directly ties into this story. It links the new long-term data for Zepbound and Foundayo with tangible capacity to supply more patients, reinforcing the importance of execution on manufacturing scale up as a key catalyst, while also raising the stakes if payer resistance or future pricing reforms slow the expected uptake of obesity treatments.

Yet behind the strong trial results, investors still need to be aware of how concentrated Lilly’s revenue is in a handful of obesity drugs and...

Eli Lilly's narrative projects $106.9 billion revenue and $42.9 billion earnings by 2029. This requires 17.9% yearly revenue growth and about a $22.3 billion earnings increase from $20.6 billion today.

Uncover how Eli Lilly's forecasts yield a $1209 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming Lilly would reach about US$102.4 billion in revenue and US$40.2 billion in earnings by 2029, yet still saw pricing reforms and safety scrutiny in obesity as powerful headwinds that could cap returns; comparing that more cautious lens with Lilly’s new long term Zepbound and Foundayo data helps you see how sharply opinions can differ and why it is worth exploring several viewpoints before deciding what you believe.

Explore 21 other fair value estimates on Eli Lilly - why the stock might be worth as much as 49% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.